MAP2K7 and melanoma: A later report on this trial involved 153 melanoma patients with ICI- or BRAF/MEK-resistant disease; treatment with lifileucel was associated 1-, 2-, 3- and 4-year os rates of 53%, 33.9%, 28.4% and 21.9% and with an ORR of 31.4%, with the median duration of response not reached [120].